QUEENSBURY, N.Y.–(BUSINESS WIRE)–Jul 23, 2026–
Delcath Programs, Inc. (Nasdaq: DCTH), an interventional oncology firm obsessed with the treatment of most most important and metastatic cancers of the liver, announced this day this can host a convention name on August 6, 2026, at 8:30 AM Eastern Time to focus on outcomes for its 2d quarter ended June 30, 2026.
Conference Call Recordsdata
To participate on this tournament, dial in approximately 5 to 10 minutes prior to the starting place of the name.
Event Date: Thursday, August 6, 2026
Time: 8:30 AM Eastern Time
Participant Numbers:
Toll Free: 1-800-717-1738
International: 1-646-307-1865
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1767384&tp_key=cbc23b55c8
A replay of the webinar will likely be on hand rapidly after the conclusion of the name and will likely be archived on the firm’s net place of dwelling right here.
About Delcath Programs, Inc., HEPZATO KIT and CHEMOSAT
Delcath Programs, Inc. is an interventional oncology firm obsessed with the treatment of most most important and metastatic liver cancers. The firm’s proprietary products, HEPZATO KIT™ (Hepzato (melphalan) for Injection/Hepatic Supply Machine) and CHEMOSAT ® Hepatic Supply Machine for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer excessive-dose chemotherapy to the liver while controlling systemic publicity and associated facet outcomes during a PHP route of.
Within the United States, HEPZATO KIT is believed to be a aggregate drug and machine product and is regulated and accredited within the marketplace as a drug by the FDA. HEPZATO KIT is constituted of the chemotherapeutic drug melphalan and Delcath’s proprietary Hepatic Supply Machine (HDS). The HDS is dilapidated to surgically isolate the liver while concurrently filtrating hepatic venous blood during melphalan infusion and washout. The utilization of the HDS outcomes in loco-regional shipping of an attractive excessive melphalan dose, which could perhaps doubtlessly induce a clinically important tumor response with minimal hepatotoxicity and within the reduction of systemic publicity. HEPZATO KIT is accredited within the United States as a liver-directed treatment for grownup patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting now now not as a lot as 50% of the liver and no extrahepatic disease, or extrahepatic disease restricted to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please seek the entire Prescribing Recordsdata, at the side of BOXED WARNING for the HEPZATO KIT.
In Europe, the machine-simplest configuration of the HDS is regulated as a Class III scientific machine and is accredited within the marketplace under the synthetic title CHEMOSAT Hepatic Supply Machine for Melphalan, or CHEMOSAT, where it has been dilapidated within the behavior of percutaneous hepatic perfusion procedures at most most important scientific centers to treat a vast sequence of cancers of the liver.
Impress source version on businesswire.com:https://www.businesswire.com/records/dwelling/20260723206368/en/
CONTACT: Investor Family Contact:
ICR Healthcare
KEYWORD: NEW YORK UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: ONCOLOGY HEALTH CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Delcath Programs, Inc.
Copyright Change Wire 2026.
PUB: 07/23/2026 04:01 PM/DISC: 07/23/2026 04:02 PM
http://www.businesswire.com/records/dwelling/20260723206368/en
